Last reviewed · How we verify
Halobetasol Topical Lotion
Halobetasol is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Halobetasol is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Severe dermatitis, psoriasis, and lichen planus (topical).
At a glance
| Generic name | Halobetasol Topical Lotion |
|---|---|
| Also known as | Halobetasol topical lotion 0.05% |
| Sponsor | Sun Pharmaceutical Industries Limited |
| Drug class | Topical corticosteroid (Class I, super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Halobetasol propionate is a Class I (super-potent) corticosteroid that penetrates skin tissue and binds to intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory responses. This mechanism makes it effective for treating severe inflammatory and allergic skin conditions.
Approved indications
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
- Severe dermatitis, psoriasis, and lichen planus (topical)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Folliculitis
- Hypertrichosis
- Acneiform eruptions
- Hypopigmentation
Key clinical trials
- Duobrii Treatment of Acne Keloidalis Nuchae (AKN) (PHASE3)
- Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (PHASE3)
- Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis (NA)
- A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis. (EARLY_PHASE1)
- Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05% (PHASE4)
- Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis (PHASE3)
- Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis (PHASE3)
- Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Halobetasol Topical Lotion CI brief — competitive landscape report
- Halobetasol Topical Lotion updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI